BOOST Pharma is based on many years of collaborative research from Karolinska Institute in Stockholm with the focus on a novel cell therapy treatment for Osteogenesis Imperfecta. The research teams of associate professor Cecilia Götherström and professor Magnus Westgren have shown that treatment with BOOST cells, called BT-101, greatly enhanced the quality of life for patients suffering from this otherwise extremely debilitating disease.